Dermatology and Oncology
Conditions
Keywords
metastatic melanoma, BRAF inhibitor, MEK inhibitor, hydroxychloroquine, autophagy
Brief summary
Patients with a BRAF mutated melanoma are usually treated in France by a first line of immunotherapy followed by a second line that combines a BRAF inhibitor (dabrafenib, vemurafenib, encorafenib) and a MEK inhibitor (trametinib, cobimetinib, binimetinib). The combination dabrafenib/trametinib is initially very efficient but it is unfortunately limited because acquired resistances usually occur after a year of treatment. Patients who become resistant to dabrafenib/trametinib and immunotherapy, unfortunately do not have an approved effective treatment at their disposal. They usually receive a palliative chemotherapy by dacarbazine or fotemustine, and they have a mean overall survival that is less than three months. Activation of autophagy in presence of BRAF and MEK inhibitors is a known mechanism of resistance to BRAF/MEK inhibitors. Hydroxychloroquine is an autophagy inhibitor and it has been suggested in vitro that it could decrease resistance to BRAF/MEK inhibitors. Following the positive results in 2018 of a phase I/II study in the USA that showed the efficacy and the absence of toxicity of the association of Dabrafenib, Trametinib and hydroxychloroquine when used as a first line treatement, we proposed to our patients who had become resistant to the dabrafenib/trametinib combination, to pursue their treatment beyond progression and to receive in addition hydroxychloroquine. This prescription was initiated in patients for whom no further therapeutic options were available, after validation by a multidisciplinary tumor board. All patients were informed that the combination dabrafenib/trametinib/hydroxychloroquine was not approved by a regulatory agency.
Interventions
OTHERpre-treatment data
We will evaluate in all patients pre-treatment data : * Melanoma staging at treatment initiation * Melanoma characteristics at initial diagnosis * Number and location of metastasis * Performans status * Demographic information
OTHERduring study treatment
We will evaluate in all patients during study treatment : * Rate of adverse events * Type of adverse events * Radiological response to treatment by CTscans that are routinely performed every three months.
Sponsors
Hospices Civils de Lyon
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with metastatic melanoma with an activating BRAF mutation * Who received at least one line of immunotherapy * Whose disease is resistant to a BRAF inhibitor used as a single agent or in combination with a MEK inhibitor * Who received either cytotoxic chemotherapy or the combination dabrafenib + trametinib + hydroxychloroquine after disease progression to dabrafenib/trametinib from January 2008 to June 2020 in the Dermatology ward of the Lyon Sud Hospital
Exclusion criteria
* Patients who did not received an immunotherapy prior to dabrafenib/trametinib treatment * Absence of tumor board validation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of progression free survival (PFS) in patients who are resistant to dabrafenib/trametinib who receive dabrafenib/trametinib/hydroxychloroquine despite tumor progression versus cytotoxic chemotherapy | Patients treated from January 2008 to June 2020 will be included retrospectively in this study. Data cut off will be defined in June 2020. | Progression Free Survival: the length of time during and after the treatment of a cancer, that a patient lives with the disease but it does not get worse |
Countries
France
Outcome results
None listed